Silence Therapeutics PLC News - SLN

Professional-Grade Tools, for Individual Investors.

FeaturedElement79 Gold Corp. Reports Significant Progress in Community Relations and Development Efforts in Chachas, Peru

Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright Global Investment Conference

Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel short...

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM...

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM...

Silence Therapeutics Reports First Quarter 2022 Results

Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel short...

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM...

H.C. Wainwright Thinks Silence Therapeutics’ Stock is Going to Recover

H.C. Wainwright analyst Patrick Trucchio maintained a Buy rating on Silence Therapeutics (SLN – Research Report) on April 4 and set a price target...

BTIG Maintains Their Buy Rating on Silence Therapeutics (SLN)

BTIG analyst Thomas Shrader maintained a Buy rating on Silence Therapeutics (SLN – Research Report) on April 3 and set a price target of $32.00...

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM...

Chardan Capital Remains a Buy on Silence Therapeutics (SLN)

In a report released today, Keay Nakae from Chardan Capital reiterated a Buy rating on Silence Therapeutics (SLN – Research Report), with a price...

Chardan Capital Initiates a Buy Rating on Silence Therapeutics (SLN)

Chardan Capital analyst Keay Nakae initiated coverage with a Buy rating on Silence Therapeutics (SLN – Research Report) today and set a price...

BTIG Thinks Silence Therapeutics’ Stock is Going to Recover

BTIG analyst Thomas Shrader reiterated a Buy rating on Silence Therapeutics (SLN – Research Report) yesterday and set a price target of $32.00...

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM...

Silence Therapeutics (SLN) Gets a Buy Rating from H.C. Wainwright

In a report released today, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Silence Therapeutics (SLN – Research Report), with a...

Annual and Transition Report (foreign Private Issuer) (20-f)

false FY 0001479615 --12-31 P10Y 1 P10Y 0 0.333 0 0 P0M 0 1 0 0.333 0 0 0 P1Y6M14D P2Y5M15D...

Monksdream 6 months ago

SLN over $20

👍️0

Monksdream 7 months ago

SLN new 52 week hi

👍️0

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Silence Therapeutics PLC (SLN)

Professional-Grade Tools, for Individual Investors.

SLN News

FeaturedElement79 Gold Corp. Reports Significant Progress in Community Relations and Development Efforts in Chachas, Peru

Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright Global Investment Conference

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

Silence Therapeutics Reports First Quarter 2022 Results

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

H.C. Wainwright Thinks Silence Therapeutics’ Stock is Going to Recover

BTIG Maintains Their Buy Rating on Silence Therapeutics (SLN)

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

Chardan Capital Remains a Buy on Silence Therapeutics (SLN)

Chardan Capital Initiates a Buy Rating on Silence Therapeutics (SLN)

BTIG Thinks Silence Therapeutics’ Stock is Going to Recover

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

Silence Therapeutics (SLN) Gets a Buy Rating from H.C. Wainwright

Annual and Transition Report (foreign Private Issuer) (20-f)

SLN Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Silence Therapeutics PLC (SLN) News

Silence Therapeutics PLC (SLN)

Professional-Grade Tools, for Individual Investors.

SLN News

FeaturedElement79 Gold Corp. Reports Significant Progress in Community Relations and Development Efforts in Chachas, Peru

Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright Global Investment Conference

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

Silence Therapeutics Reports First Quarter 2022 Results

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

H.C. Wainwright Thinks Silence Therapeutics’ Stock is Going to Recover

BTIG Maintains Their Buy Rating on Silence Therapeutics (SLN)

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

Chardan Capital Remains a Buy on Silence Therapeutics (SLN)

Chardan Capital Initiates a Buy Rating on Silence Therapeutics (SLN)

BTIG Thinks Silence Therapeutics’ Stock is Going to Recover

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

Silence Therapeutics (SLN) Gets a Buy Rating from H.C. Wainwright

Annual and Transition Report (foreign Private Issuer) (20-f)

SLN Discussion

Your Recent History